Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.

Literature DB >> 1605613

Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.

M Brun-Pascaud¹, M Fay, M Zhong, J Bauchet, A Dux-Guyot, J J Pocidalo.

Abstract

We compared the prophylactic activities of six fluoroquinolones against Pneumocystis carinii pneumonia in immunosuppressed rats. Pefloxacin was the only agent which was as effective as the reference drug trimethoprim-sulfamethoxazole. Clinical trials with pefloxacin in patients at risk for P. carinii pneumonia appear to be justified.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1992 PMID： 1605613 PMCID： PMC188460 DOI： 10.1128/AAC.36.2.470

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

25 in total

1. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors: J S Wolfson; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

2. Pulmonary involvement in the acquired immunodeficiency syndrome.

Authors: P C Hopewell; J M Luce
Journal: Chest Date: 1985-01 Impact factor: 9.410

3. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors: S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal: Antimicrob Agents Chemother Date: 1988-06 Impact factor: 5.191

4. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.

Authors: W T Hughes; V L Gray; W E Gutteridge; V S Latter; M Pudney
Journal: Antimicrob Agents Chemother Date: 1990-02 Impact factor: 5.191

5. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia.

Authors: P M Girard; M Brun-Pascaud; R Farinotti; L Tamisier; S Kernbaum
Journal: Antimicrob Agents Chemother Date: 1987-07 Impact factor: 5.191

6. Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.

Authors: B Kemmerich; K Borner; J E Pennington
Journal: Antimicrob Agents Chemother Date: 1987-03 Impact factor: 5.191

Review 3. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

Authors: P D Walzer; J Foy; P Steele; M White
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

3 in total

Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia.

1. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

2. Pulmonary involvement in the acquired immunodeficiency syndrome.

3. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

4. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis.

5. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia.

6. Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.

7. Effects of sulfonylurea compounds on Pneumocystis carinii.

8. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.

9. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis.

10. Clinical features of Pneumocystis pneumonia in the acquired immune deficiency syndrome.

1. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.

Review 2. Quinolones in the treatment of lower respiratory tract infections in adult patients.

Review 3. Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.